Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis.

Trial Profile

Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Recurrent respiratory papillomatosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Dec 2018.
    • 02 Sep 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.
    • 09 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top